GlaxoSmithKline S.A.E

BIOC

EGS38171C012

Pharmaceuticals

End-of-day quote Egyptian Exchange Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
31.56 ^EGP	-0.03%		-7.69%	-11.22%

Mar. 04	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

GlaxoSmithKline S.A.E Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021

August 11, 2021 at 06:47 pm EDT

GlaxoSmithKline S.A.E reported consolidated earnings results for the six months ended June 30, 2021. For the period, the company has posted net profit of EGP 20,650,292 against EGP 115,967,137 a year ago.

Latest news about GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 18	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-14	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-30	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
GlaxoSmithKline S.A.E Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-11	CI
Glaxosmithkline S.A.E Reports Standalone and Consolidated Financial Results for the Quarter Ended March 31, 2021	21-06-15	CI
Glaxosmithkline S.A.E Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2020	21-03-31	CI
Hikma Pharmaceuticals PLC cancelled the acquisition of GlaxoSmithKline S.A.E.	21-03-10	CI
Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares	21-02-01	CI
Hikma Pharmaceuticals PLC entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E from Glaxo Group Limited.	21-01-25	CI
GlaxoSmithKline S.A.E Reports Audited Standalone Earnings Results for the Year Ended December 31, 2019	20-04-30	CI
GSK Egypt to Launch 2 Production Lines with EGP 100 million Investments	19-11-21	CI
Glaxo Smith Kline Announces Consolidated Earning Results for the Nine Months Ended September 30, 2018	19-09-21	CI
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the First Quarter Ended March 31, 2018	18-11-26	CI
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the Six Months Ended June 30, 2018	18-11-26	CI
GlaxoSmithKline plc Declares Cash Dividends, Payable on October 18, 2018	18-10-13	CI
Glaxo Smith Kline Reports Audited Consolidated and Standalone Earnings Results for the Year Ended December 31, 2017	18-07-30	CI
Glaxo Smith Kline Announces Consolidated and Standalone Earning Results for the Nine Months Ended September 30, 2017	18-01-02	CI
Glaxo Smith Kline Announces Cash Dividend, Payable on December 28, 2017	17-12-16	CI
Glaxo Smith Kline Reports Consolidated Earnings Results for the Six Months Ended June 30, 2017	17-12-13	CI
Glaxo Smith Kline Reports Standalone Earnings Results for the Six Months Ended June 30, 2017	17-12-12	CI
Glaxo Smith Kline Reports Standalone and Consolidated Earnings Results for the Quarter Ended March 31, 2017	17-11-13	CI

Chart GlaxoSmithKline S.A.E

Duration

Period

More charts

Company Profile

GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAXOSMITHKLINE S.A.E	-11.22%	54.86M
ELI LILLY AND COMPANY	+26.96%	672B
NOVO NORDISK A/S	+26.84%	570B
JOHNSON & JOHNSON	-6.21%	360B
MERCK & CO., INC.	+15.37%	321B
ABBVIE INC.	+8.24%	300B
ASTRAZENECA PLC	+7.11%	217B
ROCHE HOLDING AG	-9.45%	204B
NOVARTIS AG	+5.48%	199B
PFIZER, INC.	-9.41%	149B